Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.49 |
| ▸ | PREP | P48147 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | FAP | Q12884 | 3/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | MVD | P53602 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380104 | 1.00 | ACE (0.49) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL31670618 | 0.95 | ACE (0.45) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL31265373 | 0.95 | ACE (0.45) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL29985759 | 0.91 | PREP (0.44) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL8564779 | 0.88 | DPP4 (0.46) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL8564777 | 0.88 | DPP4 (0.46) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL15756757 | 0.87 | ACE (0.53) | ACEMVDREN | |
| SCHEMBL13246638 | 0.87 | ACE (0.53) | ACEMVDREN | |
| SCHEMBL29935652 | 0.87 | CHRM3 (0.42) | PREPDPP4FAPDPP8DPP9 | |
| Glycyl Proline SCHEMBL155067 | 0.86 | ACE (0.62) | ACEPREPDPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606430-A2 | USE OF IL-22 DIMER IN MANUFACTURE OF A MEDICAMENT FOR INTRAVENOUS ADMINISTRATION | Evive Biotechnology (Shanghai) Ltd (CN) | 2025-08-27 | — | — | EP | disclosed |
| EP-3808369-B1 | USE OF IL-22 DIMERS IN MANUFACTURE OF A MEDICAMENT FOR INTRAVENOUS ADMINISTRATION | EVIVE BIOTECHNOLOGY SHANGHAI LTD (CN) | 2025-03-26 | — | — | EP | disclosed |
| EP-3065763-B2 | USE OF IL-22 DIMER IN MANUFACTURE OF A MEDICAMENT FOR INTRAVENOUS ADMINISTRATION | EVIVE BIOTECHNOLOGY SHANGHAI LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230301901-A1 | USE OF IL-22 DIMER IN MANUFACTURE OF A MEDICAMENT FOR INTRAVENOUS ADMINISTRATION | Evive Biotechnology (Shanghai) Ltd (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-109328069-B | Use of IL-22 in the treatment of necrotizing enterocolitis | 亿一生物医药开发(上海)有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116670161-A | Methods of preventing or treating viral-induced organ injury or failure using IL-22 dimers | 亿一生物医药开发(上海)有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11654104-B2 | Use of IL-22 dimer in manufacture of a medicament for intravenous administration | Evive Biotechnology (Shanghai) Ltd (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20230079150-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2023-03-16 | — | — | US | disclosed |
| EP-4103219-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-11510966-B2 | Use of IL-22 in treating necrotizing enterocolitis | Evive Biotechnology (Shanghai) Ltd (CN) | 2022-11-29 | — | — | US | disclosed |
| EP-3442562-B1 | AN IL-22 DIMER FOR USE IN TREATING NECROTIZING ENTEROCOLITIS | EVIVE BIOTECHNOLOGY SHANGHAI LTD (CN) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301901-A1 | USE OF IL-22 DIMER IN MANUFACTURE OF A MEDICAMENT FOR INTRAVENOUS ADMINISTRATION | IL2, IL2RA, IL36G | ACE 2724/4885PREP 1150/4885DPP4 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.